Clinical trial Recruiting at 20 sites Phase 3 Interventional Ages 10 to 17

Evaluating Ozanimod versus Fingolimod for Children with Relapsing Remitting Multiple Sclerosis

Official title: A Phase 3, Multicenter, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Run by Bristol-Myers Squibb · NCT06408259 · Data updated 2026-11-12

This study is testing whether ozanimod works better than fingolimod for children and teens with relapsing remitting multiple sclerosis.

Quick facts

PhasePhase 3
Study typeInterventional
Ages10 Years to 17 Years
SexAll
Enrollment194 (estimated)
SponsorBristol-Myers Squibb
Industry-sponsored
Locations33 sites (Loma Linda, California and 32 other locations)
StatusRecruiting
StartedApril 8, 2025
Main results expectedApril 11, 2031
Study endsJuly 13, 2036
Registry record updatedSeptember 10, 2026
Trial IDNCT06408259 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are children and adolescents diagnosed with relapsing remitting multiple sclerosis who have experienced recent disease activity.

Probably not a fit

Patients with progressive forms of multiple sclerosis or other significant immune system diseases may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the effectiveness and safety of ozanimod compared to fingolimod in treating children and adolescents diagnosed with relapsing remitting multiple sclerosis (RRMS). Participants will receive either ozanimod, fingolimod, or a placebo, and the study will monitor drug levels, effects, and tolerability. The research focuses on individuals who have experienced recent disease activity, ensuring a targeted approach to treatment evaluation.

Why it matters

Potential benefit: If successful, this study could provide a new effective treatment option for children and adolescents with relapsing remitting multiple sclerosis.

How similar studies have gone: Previous studies have shown promise in evaluating treatments for multiple sclerosis, but this specific comparison of ozanimod and fingolimod in a pediatric population is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Has a diagnosis of multiple sclerosis (MS) as defined by the 2017 revision of the McDonald Criteria with a relapsing remitting course of disease.
* Meets at least 1 of the following criteria for disease activity:

  i) At least 1 MS relapse/attack in the previous year prior to screening.

ii) At least 2 MS relapses/attacks in the previous 2 years prior to screening.

iii) Evidence of 1 or more gadolinium-enhancing (GdE) lesions on magnetic resonance imaging (MRI) within 6 months prior to baseline (including screening MRI).

\- Has an Expanded Disability Status Scale (EDSS) score of 0 to 5.5, both inclusive.

Exclusion Criteria:

* Diagnosis of progressive forms of MS.
* Active or chronic disease of the immune system other than MS.
* Clinically relevant cardiovascular, hepatic, neurological other major systematic disease.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Where it's running

  • University of California Davis Health
    Sacramento, California, United States
    Recruiting
  • University of South Florida
    Tampa, Florida, United States
    Recruiting
  • University of Chicago Medical Center
    Chicago, Illinois, United States
    Recruiting
  • University of Louisville, Norton Children's Research Institute
    Louisville, Kentucky, United States
    Recruiting
  • Medical College of Wisconsin
    Milwaukee, Wisconsin, United States
    Recruiting
  • Royal Children's Hospital
    Melbourne, Victoria, Australia
    Recruiting
Show 27 more locations
  • University of Naples Federico II
    Naples, Campania, Italy
    Recruiting
  • Ospedale San Raffaele
    Milan, Lombardy, Italy
    Recruiting
  • Neurological Center Of Latium
    Rome, Roma, Italy
    Recruiting
  • 2Ca Braga
    Braga, Portugal
    Recruiting
  • Unidade Local de Saúde de Coimbra, E.P.E.
    Coimbra, Portugal
    Recruiting
  • Centro Hospitalar de Lisboa Central
    Lisbon, Portugal
    Recruiting
  • Spitalul Clinic de Copii Doctor Victor Gomoiu
    Bucharest, Bucharest, Romania
    Recruiting
  • Prof. Dr. Alexandru Obregia Psychiatry Hospital
    Bucharest, Bucharest, Romania
    Recruiting
  • CHUVI- Hospital Alvaro Cunqueiro
    Vigo, Pontevedra [Pontevedra], Spain
    Recruiting
  • Hospital Universitario Virgen Macarena
    Seville, Spain
    Recruiting
  • Hospital Universitari i Politecnic La Fe
    Valencia, Spain
    Recruiting
  • Hospital Universitario Miguel Servet
    Zaragoza, Spain
    Recruiting
  • National Taiwan University Hospital
    Taipei, Taiwan
    Recruiting
  • Ondokuz Mayıs Universitesi
    Samsun, Turkey (Türkiye)
    Recruiting
  • Local Institution - 0114
    Loma Linda, California, United States
    Not yet recruiting
  • Local Institution - 0093
    Chicago, Illinois, United States
    Withdrawn
  • Local Institution - 0131
    New Brunswick, New Jersey, United States
    Not yet recruiting
  • Local Institution - 0132
    Teaneck, New Jersey, United States
    Withdrawn
  • Local Institution - 0091
    Cincinnati, Ohio, United States
    Withdrawn
  • Local Institution - 0092
    Portland, Oregon, United States
    Not yet recruiting
  • Local Institution - 0133
    El Paso, Texas, United States
    Not yet recruiting
  • Local Institution - 0081
    Milan, Lombardy, Italy
    Not yet recruiting
  • Local Institution - 0078
    Mexico City, Dif, Mexico
    Withdrawn
  • Local Institution - 0108
    Poznan, Greater Poland Voivodeship, Poland
    Completed
  • Local Institution - 0102
    Porto, Portugal
    Withdrawn
  • Local Institution - 0134
    Caguas, Puerto Rico
    Not yet recruiting
  • Local Institution - 0096
    Esplugues de Llobregat, Barcelona [Barcelona], Spain
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.